DiscoveryBioMed, Inc. (DBM), Birmingham, AL, has been awarded a $200,000 Small Business Innovations Research (SBIR) Phase 1 grant by the National Institutes of Health (NIH) to continue research into the discovery and development of anti-inflammatory phytochemicals to address complications associated with nasal and pulmonary inflammation, dermatitis and kidney disorders with an inflammatory component. DBM will be working with ChromaDex Corp., which will be providing a library of natural products and phytochemicals to screen in their human cell platform.